Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13116322 | 0.87 | PTGDR2 (0.74) | PTGDR2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL13116270 | 0.86 | TRPM8 (0.51) | PTGDR2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL2817200 | 0.85 | PTGDR2 (0.50) | PTGDR2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL2817866 | 0.85 | PTGDR2 (0.50) | PTGDR2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL13116304 | 0.85 | PTGDR2 (0.71) | PTGDR2KDM4EALDH1A1CYP1A2CYP2C9 | |
| Dimethylamine SCHEMBL2820162 | 0.85 | PTGDR2 (0.65) | PTGDR2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL2821829 | 0.84 | PTGDR2 (0.74) | PTGDR2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL13116332 | 0.84 | PTGDR2 (0.57) | PTGDR2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL13116326 | 0.78 | PTGDR2 (0.53) | PTGDR2KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL13116311 | 0.78 | PTGDR2 (0.49) | PTGDR2KDM4EALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127527-A1 | Large conductance calcium-activated k channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-01 | — | — | US | claimed |
| EP-1432690-A2 | IMIDAZOLE, THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PREVENTION OF POLLAKIURIA OR URINARY INCONTINENCE | Tanabe Seiyaku Co., Ltd. (JP) | 2004-06-30 | — | — | EP | claimed |
| WO-2002083111-A2 | IMIDAZOLE, THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PREVENTION OF POLLAKIURIA OR URINARY INCONTINENCE | TANABE SEIYAKU CO., LTD. (JP) | 2002-10-24 | — | — | WO | claimed |
| US-20100256165-A1 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | HONGU MITSUYA | 2010-10-07 | — | — | US | disclosed |
| US-20100256165-A1 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | HONGU MITSUYA | 2010-10-07 | — | — | US | disclosed |
| US-20100256165-A1 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | HONGU MITSUYA | 2010-10-07 | — | — | US | disclosed |
| US-7759373-B2 | Large conductance calcium-activated K channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-20 | — | — | US | disclosed |
| US-7759373-B2 | Large conductance calcium-activated K channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-20 | — | — | US | disclosed |
| US-7759373-B2 | Large conductance calcium-activated K channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-20 | — | — | US | disclosed |
| US-20040127527-A1 | Large conductance calcium-activated k channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1432690-A2 | IMIDAZOLE, THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PREVENTION OF POLLAKIURIA OR URINARY INCONTINENCE | Tanabe Seiyaku Co., Ltd. (JP) | 2004-06-30 | — | — | EP | disclosed |
| WO-2002083111-A2 | IMIDAZOLE, THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PREVENTION OF POLLAKIURIA OR URINARY INCONTINENCE | TANABE SEIYAKU CO., LTD. (JP) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256165-A1 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | KCNN3, KCNN2, KCNN1 | PTGDR2 1487/4885KDM4E 801/4885ALDH1A1 4600/4885 |
| US-20040127527-A1 | Large conductance calcium-activated k channel opener | KCNN1, KCNN4, KCNN3 | PTGDR2 2228/4885KDM4E 687/4885ALDH1A1 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.